Pharm-Olam's response to COVID-19 from CEO Rob Davie, PhD. Read Here
Check out our latest white paper! We partnered with Informa Pharma Intelligence to bring you the latest information on COVID-19 and its effect on the clinical landscape.
Rare disease drug development varies from the pathways seen in more established indications. The sample sizes are often...
In rare disease, every patient matters and it is important for CRO and sponsor medical staff to effectively monitor and...
Pharm-Olam is a clinical research organization (CRO) that has vast experience in rare diseases. To date, we have completed...
Pharm-Olam is a clinical research organization (CRO) with global reach and deep expertise in rare disease research. Our...
Tags: Rare & Orphan Disease
Pharm-Olam has been taking a closer look at trends in rare disease research. We started off by reviewing an article that was...
At Pharm-Olam, we have been focusing on trends in rare disease research. We reviewed an article from Nature (click here to...
At Pharm-Olam, we go the distance in rare disease. Recently, we have been exploring the subject in greater detail. We started...
Tags: Rare & Orphan Disease
Rare disease research is such a complicated area because it involves every therapeutic area individually and sometimes in...
Tags: Rare & Orphan Disease
Subscribe to our blog and we'll give you our GDPR Controller & Processor Checklist.
